Caspase 1 ELISA 试剂盒

• Frequently cited in scientific publications with 300+ citations
• Validated inhouse for relevant applications
• Extensive validation report for IF provided by one of your peers
• Designed to detect RFP and its variants

• Multiplex ELISA: Testing 5 Targets in 1 Run
• High performance COVID-19 antibody testing
• 99.6% specificity, 95.9% sensitivity

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.429 (epsilon), and B.1.525 (eta).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope.
• No interference with the ACE2 binding site.

• Dendra2 Antibody (ABIN361314) independently validated for Immunocytochemistry by Neurology Lab (INSERM).
• Publications cite use for Immunoblotting as well as Immunostaining.
• Dendra2 belongs to a new class of photoactivatable fluorescent proteins (PAFPs). PAFPs allow to photolable and track fusion proteins in vivo. Dendra2 Antibody (ABIN361314) can be used for control purposes in this setting.

• Magnetic agarose concanavalin A beads for CUT&RUN and CUT&Tag assays.
• Superior handling compared to magnetic silica concanavalin A beads: easier washes and resuspension.
• Reduced risk for samples to dry out.
• Performance comparable to or better than magnetic silica concanavalin A beads.

• Recombinant SARS-CoV-2 spike protein produced in HEK-293.
• Contains the E484K mutation (present in the novel lineage 501Y.S2 from South Africa) that can affect antibody recognition and enable SARS-CoV-2 immune escape.
• Contains the D614G mutation that renders SARS-CoV-2 infection and replication more efficient.

• Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
• Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

• Recombinant SARS-CoV-2 spike protein RBD produced in HEK-293.
• Contains the spike protein N501Y mutation (present in the novel lineages B.1.1.7 and 501Y.S2) that has been associated with an increased transmission rate of SARS-CoV-2.

• Simultaneous detection of Sp Cas9 binding and cleavage sites in genomic DNA.
• In situ assay leaves cells intact and reduces background.
• Unbiased detection of off-site effects because it is not based on a predictive algorithm.

• Detection of SARS-CoV-2 with variety of different immunoassays, i.e. ELISA, Lateral Flow, as validated by numerous publications (see below).
• Nucleocapsid antibody used for diagnostic Covid19 testing as well as for drug discovery.
• Developed and manufactured in the U.S.

• Has been shown to neutralize SARS-Cov-2 S protein RBD from lineages B.1.1.7, B.1.351, P.1, and B.1.429.
• Suitable as positive control in neutralization antibody screening.
• Humanized chimeric antibody consisting of human IgG1 constant domains and murine variable regions.

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
• Contains E154K, L452R, E484Q, D614G, and P681R mutations characteristic for the SARS-CoV-2 kappa variant (B.1.617.1).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.525.
• Contains Q52R, del 69-70, del 144, E484K, F888L, and Q677H mutations characteristic for the SARS-CoV-2 eta variant (B.1.525).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.429.
• Contains S13I, W152C, L452R, and D1183Y mutations characteristic for the SARS-CoV-2 eta variant (B.1.429).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.7.
• Contains del 69-70, del 144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H mutations characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern P.1.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.617.
• Contains T19R, L452R, T478K, D614G, P681R and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).

• Recombinant trimeric S protein of the SARS-CoV-2 variant of interest B.1.621 mu.
• Contains T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N mutations characteristic for the SARS-CoV-2 mu variant (B.1.621).

• NLRP3 antibody for reliable recognition of mouse and human NLRP3/NALP3
• This un-conjugated monoclonal antibody has 60 PubMed citations

• 95+ publication references, 1 independent validation
• Frequently used as CUT&RUN IgG negative control and CUT&Tag secondary antibody
• Used in CUT&RUN and CUT&Tag protocols, e.g. Henikoff et al. (2018) PMID 29651053, Kaya-Okur et al. (2019, 2020) PMID 31036827 and PMID 32913232

• Recombinant trimeric S protein of the SARS-CoV-2 variant of concern B.1.1.529 omicron (21K).
• Contains A67V, H69del, V70del, T95I, G142del, V143del, Y144del, Y145D, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F mutations characteristic for the SARS-CoV-2 omicron variant (B.1.1.529).

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
• Contains T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
• Intact furin cleavage site 680-SRRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.617.2 delta expressed in insect cells.
• Contains EFR157-158 deletion, T19R, G142D, E156G, FR157-158 deletion, L452R, T478K, D614G, P681R, and D950N mutations characteristic for the SARS-CoV-2 delta variant (B.1.617.2).
• Intact furin cleavage site 680-SRRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, and T1027I mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern P.1 gamma expressed in insect cells.
• Contains L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F mutations characteristic for the SARS-CoV-2 gamma variant (P.1).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains D80A, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 (M1-P1213) of the SARS-CoV-2 variant of concern B.1.351 expressed in insect cells.
• Contains L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, and A701V mutations characteristic for the SARS-CoV-2 beta variant (B.1.351).
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
• Contains HV69-70 deletion, Y145 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
• Intact furin cleavage site 680-SHRRAR|SV-687.
• C-terminal His-tag.

• Recombinant S protein S1+S2 ECD (M1-P1213) of the SARS-CoV-2 variant of concern B.1.1.7 expressed in insect cells.
• Contains HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H characteristic for the SARS-CoV-2 alpha variant (B.1.1.7).
• Intact furin cleavage site 680-SHRRAR|SV-687.
• C-terminal His-tag.

• Recombinant SARS-CoV-2 wt S protein S1+S2 (M1-P1213) expressed in insect cells.
• Contains D614G mutation.
• Intact furin cleavage site 680-SPRRAR|SV-687.
• C-terminal His-tag.

• High-affinity single-domain antibody
• Recognizes mRFP, mCherry, mScarlet-i, tdTomato, dsRed etc.
• Bead size 50-150 μm

• Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
• Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta) and B.1.1.529 (omicron).
• Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

• Monoclonal murine neutralizing antibody (nAb) against SARS-CoV-2 S protein.
• Binds SARS-CoV-2 S proteins of various lineages, including B.1.617.2 (delta). Does NOT bind the S protein of SARS-CoV-2 B.1.1.529 (omicron).
• Ideal for SARS-CoV-2 S-protein ELISAs and neutralization assays.

• Rabbit beta-Catenin antibody reliably detects beta-Catenin targets in Wnt-signaling using CUT&RUN, ICC, IF, WB, ELISA.
• Well suited to image adherens junctions in IHC/IF.
• Highly specific beta-Catenin detection in WB.

• Rabbit anti-CRBN Antibody reliably detects CRBN in human species.
• Polyclonal, unconjugated antibody for ELISA, WB, IHC.
• Highly specific CRBN detection. See validation images.

• Mouse IL-1 beta ELISA kit for quantitative detection of IL-1 beta.
• Reliable product with validated components.
• ELISA kit cited in more than 40 PubMed References.

• Magnetic agarose Concanavalin A beads for affinity chromatography using a magnetic separator.
• Easy bench-top purification of viruses, virus-like particles (VLP), and cultured cells via reversible binding of glycoproteins, glycolipids, or polysaccharides with terminal mannose or glucose to concanavalin A.

• Polyclonal, unconjugated GFP antibody for reliable detection of GFP and its variants.
• Validated for Fluorescence Microscopy, ELISA, Western Blotting
• High Quality GFP antibody, cited in more than 177 PubMed References.
• Available in 10 µl and 100 µl quantities.

• Reliable Taurine Assay Kit for measurement of free taurine in biological samples.
• Sample taurine concentrations are determined by comparison with a known taurine standard.
• Quick and easy to use.

• Impurity detection in the manufacturing of biological drugs.
• The AccuSignal™ Nuclease ELISA Kit is designed for sensitive and reliable quantification of nucleases in therapeutic products, including DENARASE®, Benzonase®, and Turbonuclease.
• Offers a broad quantification spectrum, maintaining outstanding dilution linearity, instilling trust in the accuracy of results over a wide array of nuclease concentrations.
• Delivers consistent and repeatable outcomes, characterized by minimal intra- and inter-assay variability.
• Tailored antibody specificity allows for application across diverse materials, accommodating various nuclease products from multiple suppliers.
• Components: 96-well strip plate, plate sealer, nuclease standard, biotinylated detection antibody, Streptavidin-HRO (100X), buffers.

• High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose magnetic beads with 50-150 µm diameter.
• The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
• Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

• High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of human serum albumin.
• PBS-only, preservative free
• 15 PubMed references available for this FcRn antibody.

• High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of IgG.
• PBS-only, preservative free
• 2 PubMed references available for this FcRn antibody.

• High-affinity anti-GFP single-domain antibody (sdAb) covalently bound to 4 % cross-linked agarose beads with 50-150 µm diameter.
• The Alpaca sdAb clone 1H1 is specific for GFP and many GFP derivatives. Capacity > 3 μg GFP per μl of packed beads.
• Compatible with physiological buffers, common Lysis and Wash Buffers, and high stringency buffers.

• TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 18-8816-33

• TrueBlot®: Anti-Rabbit IgG HRP, Mouse Monoclonal eB182
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 18-8816-31

• Anti-ATM Protein Kinase pS1981 (MOUSE) Monoclonal Antibody
• Manufactured by Rockland Immunochemicals, Inc.
• Rockland Product ID: 200-301-400

• High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of human serum albumin.
• contains Glycerol for better storage.

• High-quality FcRn antibody (Clone DVN24) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of IgG.
• Contains Glycerol for better storage.

• Microtiter plate (96 wells stripwell) - 1
• Enzyme conjugate - 1 vial
• Standard A - 1 vial
• Standard B - 1 vial
• Standard C - 1 vial
• Standard D - 1 vial
• Standard E - 1 vial
• Standard F - 1 vial
• Substrate A - 1 vial
• Substrate B - 1 vial
• Stop solution - 1 vial
• Wash solution - 1 vial
• Balance solution - 1 vial
• Instruction manual - 1

• Precision pipettors and disposable tips to deliver 10-1000 μL. A multi-channel pipette is desirable for large assays.
• 100 mL and 1 L graduated cylinders.
• Distilled or deionized water
• Tubes to prepare sample dilutions.
• Absorbent paper.
• Microplate reader capable of measuring absorbance at 450 nm.
• Centrifuge capable of 3000 x g.
• Microplate washer or washing bottle.
• Incubator (37 °C).
• Data analysis and graphing software.

Our GFP Catcher is a product based on the GFP pull-down technique used to isolate GFP fusion proteins from cell lysates. It consists of special magnetic beads (product ABIN7272855) or agarose beads (product ABIN5311508) coated with an antibody against GFP. These beads allow efficient and selective binding to GFP or GFP-fused target proteins.

The application of GFP Catcher is similar to the GFP pull-down method. First, the protein of interest is expressed in the cells with it fused to GFP. Then, the cell lysate is prepared to extract the target proteins. The GFP catcher beads are then added to the cell lysate and bound to these proteins by specifically binding to the GFP or GFP fusion protein.

After the beads with the bound target proteins are isolated, thorough purification is performed to remove components that are not specifically bound. Finally, the target proteins can be separated from the beads and used for further analysis such as immunoblotting or mass spectrometry.

GFP Catcher offers the advantage of quick and easy isolation of GFP fusion proteins. It is a useful tool for protein analysis and allows efficient identification of proteins interacting with GFP fusion protein. GFP Catcher is widely used in cell biology research to study protein-protein interactions and deepen the understanding of cellular processes.

• The supplier is only responsible for the kit itself, but not for the samples consumed during the assay. The user should calculate the possible amount of samples used in the whole test. Please reserve sufficient amounts of samples in advance.
• Please predict the concentration before assaying. If values for these are not within the range of the standard curve, users must determine the optimal sample dilutions for their particular experiments.
• If the samples are not indicated in the manual, a preliminary experiment to determine the validity of the kit is necessary.
• Owing to the possibility of mismatching between antigens from another resource and antibodies used in this supplier's kits (e.g., antibody targets conformational epitope rather than linear epitope), some native or recombinant proteins from other manufacturers may not be recognized by this supplier's products.
• Influenced by factors including cell viability, cell number and cell sampling time, samples from cell culture supernatant may not be recognized by the kit.
• Fresh samples without long time storage are recommended for the test. Otherwise, protein degradation and denaturalization may occur in those samples and finally lead to wrong results.

• It is recommended that all standards, controls and samples be run in duplicate. Standards and samples must be assayed at the same time.
• The coefficient of determination of the standard curve should be higher or equal 0.95 and the highest O.D. should be more than 1.0.
• Cover or cap all kit components and store at 2-8°C when not in use.
• Microtiter plates should be allowed to come to room temperature before opening the foil bags. Once the desired number of strips has been removed, immediately reseal the bag with desiccants and store at 2-8°C to maintain plate integrity.
• Samples should be collected in pyrogen/endotoxin-free tubes.
• Samples should be frozen if not analyzed shortly after collection. Avoid multiple freeze-thaw cycles of frozen samples. Thaw completely and mix well prior to analysis.
• When possible, avoid use of badly hemolyzed or lipemic serum. If large amounts of particulate matter are present, centrifuge or filter prior to analysis.
• When pipetting reagents, maintain a consistent order of addition from well-to-well. This ensures equal incubation times for all wells.
• Do not mix or interchange different reagent lots from various kit lots.
• Do not use reagents after the kit expiration date.
• Read absorbance immediately after adding the stop solution.
• Incomplete washing will adversely affect the test outcome. All washing must be performed with Wash Solution provided. All residual wash liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
• Because TMB is light sensitive, avoid prolonged exposure to light. Also avoid contact between TMB and metal, otherwise color may develop.

• Samples - Please predict the concentration before assaying. If concentrations are unknown or not within the detection range, a preliminary experiment is recommended to determine the optimal dilution. PBS (pH 7.0-7.2) or 0.9% physiological saline can be used as dilution buffer.
• Wash solution - Dilute 10mL of wash solution concentrate (100×) with 990mL of deionized or distilled water to prepare 1000mL of wash solution (1×). If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have dissolved. The 1× wash solution is stable for 2 weeks at 2-8°C.

• Bring all kit components and samples to room temperature (20-25°C) before use.
• Do not dilute other ready-to-use components.

• Serum: Use a serum separator tube and allow samples to clot for 2 hours at room temperature or overnight at 2-8°C. Centrifuge at approximately 1000 × g (or 3000rpm) for 15 minutes. Remove serum and assay immediately or aliquot and store samples at -20°C or -80°C.
• Plasma: Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at 100 × g (or 3000rpm) at 2-8°C within 30 minutes of collection. Assay immediately or aliquot and store samples at -20°C or -80°C.
• Tissue homogenates: The preparation of tissue homogenates will vary depending upon tissue type. For this assay, thoroughly rinse tissues in ice-cold PBS (0.02mol/L, pH 7.0-7.2) to remove excess blood and weigh before homogenization. Mince the tissues into small pieces and homogenize them in a certain amount of PBS with a glass homogenizer on ice. Subject the resulting suspension to ultrasonication or to two freeze-thaw cycles to further break down cell membranes. After that, centrifuge for 15 minutes at 1500 × g (or 5000rpm). Remove the supernate and assay immediately or aliquot and store samples at -20°C or -80°C.
• Cell lysates: Cells should be lysed according to the following directions.
  • 1. Adherent cells should be detached with trypsin and then collected by centrifugation. Suspension cells can be collected by centrifugation directly.
  • 2. Wash three times in PBS.
  • 3. Resuspend cells in PBS and subject to ultrasonication 3 times. Alternatively, freeze cells at -20°C. Thaw cells with gentle mixing. Repeat the freeze/thaw cycle 3 times.
  • 4. Centrifuge at 1000 × g (or 3000rpm) for 15 minutes at 2-8°C to remove cellular debris.
  • 5. Assay immediately or store samples at -20°C or -80°C.
• Cell culture supernatants and other body fluids: Centrifuge cell culture media at 1000 × g (or 3000rpm) for 15 minutes to remove debris. Assay immediately or store samples at -20°C or -80°C.

• Samples should be aliquoted and must be stored at -20°C (lower or equal 3 months) or -80°C (lower or equal 6 months) to avoid loss of bioactivity and contamination. If samples are to be run within 24 hours, they may be stored at 2-8°C. Avoid repeated freeze-thaw cycles.
• Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.
• Tissue or cell extraction samples prepared by chemical lysis buffer may cause unexpected ELISA results due to the impacts of certain chemicals.
• Samples containing a visible precipitate must be clarified prior to use in the assay. Care should be taken to minimize hemolysis. Do not use grossly hemolyzed or lipemic specimens.
• Do not use heat-treated specimens.

• The standard curve is used to determine the amount of samples.
• First, average the duplicate readings for each standard and sample. All O.D. values are subtracted by the mean value of blank control well. DO NOT subtract the O.D. of standard zero.
• Construct a standard curve by plotting the average O.D. for each standard on the vertical (Y) axis against the concentration on the horizontal (X) axis and draw a best fit curve using graph paper or statistical software to generate a four parameter logistic (4-PL) curve fit or logit log linear regression curve. An x-axis for the optical density and a y-axis for the concentration is also a choice. The data may be linearized by plotting the log of the concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis.
• Calculate the concentration of samples corresponding to the mean absorbance from the standard curve.

• Any variation in operator, pipetting and washing technique, incubation time/temperature and kit age can cause variation in result. Each user should obtain their own standard curve.
• If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
• If specimen generate values higher than the highest standard, dilute the specimens and repeat the assay.

• This kit contains a small amount of 3, 3’, 5, 5’-Tetramethylbenzidine (TMB) in Substrate B. TMB is non-carcinogenic but it is hazardous in case of skin contact, eye contact, ingestion and inhalation. In case of contact, rinse affected area with plenty of water.
• The stop solution provided with this kit is an acid solution. Wear protective gloves, clothing, and face protection.
• Care should be taken when handling the standard because of the known and unknown effects of it.
• Care should also be taken to avoid contact of skin or eyes with other kit reagents or specimens. In the case of contact, wash immediately with water.
• Do not pipette by mouth.
• Avoid generation of aerosols.
• Waste must be disposed of in accordance with federal, state and local environmental control regulations.
• All blood components and biological materials should be handled as potentially hazardous. Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour a 121.5°C.

• The user should calculate the possible amount of the samples used in the whole test. Please reserve sufficient amount of samples in advance.
• Please predict the concentration before assaying. If values for these are not within the range of the standard curve, users must determine the optimal sample dilutions for their particular experiments.
• If the samples are not indicated in the manual, a preliminary experiment to determine the validity of the kit is necessary.
• Owing to the possibility of mismatching between antigen from other resource and antibody used in our kits (e.g., antibody targets conformational epitope rather than linear epitope), some native or recombinant proteins from other manufacturers may not be recognized by our products.
• Influenced by the factors including cell viability, cell number and also sampling time, samples from cell culture supernatant may not be detected by the kit.
• Fresh samples without long time storage are recommended for the test. Otherwise, protein degradation and denaturalization may occur in those samples and finally lead to wrong results.
• It is recommended that all standards, controls and samples be run in duplicate. Standards and samples must be assayed at the same time.
• The coefficient of determination of the standard curve should be higher or equal 0.95 and the highest O.D. should be more than 1.0.
• Cover or cap all kit components and store at 2-8° C when not in use.
• Microtiter plates should be allowed to come to room temperature before opening the foil bags. Once the desired number of strips has been removed, immediately reseal the bag with desiccants and store at 2-8°C to maintain plate integrity.
• Samples should be collected in pyrogen/endotoxin-free tubes.
• Samples should be frozen if not analyzed shortly after collection. Avoid multiple freeze-thaw cycles of frozen samples. Thaw completely and mix well prior to analysis.
• When possible, avoid use of badly hemolyzed or lipemic serum. If large amounts of particulate matter are present, centrifuge or filter prior to analysis.
• When pipetting reagents, maintain a consistent order of addition from well-to-well. This ensures equal incubation times for all wells.
• Do not mix or interchange different reagent lots from various kit lots.
• Do not use reagents after the kit expiration date.
• Read absorbance immediately after adding the stop solution.
• Incomplete washing will adversely affect the test outcome. All washing must be performed with Wash Solution provided. All residual wash liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
• Because TMB is light sensitive, avoid prolonged exposure to light. Also avoid contact between TMB and metal, otherwise color may develop.